Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Residual Clear all
Terminated Phase 2 Interventional Results available

Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

NCT01258933
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Ofatumumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 15, 2026, 10:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Intensive Speech Motor Chaining Treatment for Residual Speech Sound Disorders

NCT05929859
View directory record Official record
Conditions
Speech Sound Disorder
Interventions
Speech Motor Chaining
Behavioral
Lead sponsor
Syracuse University
Other
Eligibility
9 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Active, not recruiting Phase 1 Interventional

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

NCT03233854
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive
Interventions
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Questionnaire Administration, NKTR-255
Biological · Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2035
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 15, 2026, 10:27 AM EDT
Not yet recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

NCT07593079
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions
Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3, PROSTest
Drug · Device · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 4 Interventional Results available

Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability

NCT01464229
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Iloperidone, Placebo
Drug
Lead sponsor
Maurizio Fava, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 15, 2026, 10:27 AM EDT
Terminated Phase 1Phase 2 Interventional

Feasibility of the LUM Imaging System for Detection of Prostate Cancer

NCT03441464
View directory record Official record
Conditions
Prostate Cancer, Neoplasm, Residual
Interventions
LUM Imaging System
Combination Product
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 15, 2026, 10:27 AM EDT
Terminated No phase listed Observational

Electromyographic Assessment of Onset and Recovery of Neuromuscular Blockade

NCT01678625
View directory record Official record
Conditions
Residual Neuromuscular Blockade
Interventions
Train-of-four ratio calculation (T4-EMG)
Device
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

COPD Circuit Exercise

NCT05395390
View directory record Official record
Conditions
OSA, Covid19, Residual Symptoms of COVID 19, COPD
Interventions
Exercise (Resistance Training
Behavioral
Lead sponsor
Texas A&M University
Other
Eligibility
30 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 15, 2026, 10:27 AM EDT
Recruiting Phase 2 Interventional

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

NCT06773208
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Azacitidine (AZC), Venetoclax
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Recruiting Phase 2 Interventional

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

NCT06144606
View directory record Official record
Conditions
B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia
Interventions
Tecartus
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 4 Interventional Results available

Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia

NCT02034474
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 59 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 15, 2026, 10:27 AM EDT
Not yet recruiting Phase 2 Interventional

Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

NCT07690891
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Nemtabrutinib, Venetoclax, Obinutuzumab
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Not applicable Interventional Results available

Electrical Stimulation for the Treatment of Post-Amputation Pain Using the SPRINT System

NCT01996254
View directory record Official record
Conditions
Post-Amputation Pain, Phantom Limb Pain, Residual Limb Pain
Interventions
SPRINT Peripheral Nerve Stimulation (PNS) System
Device
Lead sponsor
SPR Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
10
States / cities
Scottsdale, Arizona • La Jolla, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 15, 2026, 10:27 AM EDT
Not yet recruiting Phase 2 Interventional

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

NCT07517705
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy
Radiation · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Completed No phase listed Observational

Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis

NCT02555969
View directory record Official record
Conditions
Amyloidosis, Primary Amyloidosis
Interventions
Not listed
Lead sponsor
Tufts Medical Center
Other
Eligibility
Not listed
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Sep 15, 2026, 10:27 AM EDT
Active, not recruiting No phase listed Observational

The OPBC-07/microNAC Study

NCT06529302
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years to 100 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 15, 2026, 10:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Valproate for the Treatment of Residual Amblyopia

NCT07226141
View directory record Official record
Conditions
Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic
Interventions
Valproate, Placebo, Patch
Drug · Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Active, not recruiting Phase 1 Interventional

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT02159495
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia, Late Relapse of Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia, Adult Acute Lymphoblastic Leukemia, Interleukin-3 Receptor Subunit Alpha Positive, Minimal Residual Disease, Refractory Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
cyclophosphamide, Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes, laboratory biomarker analysis, Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes, Fludarabine Phosphate
Drug · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab in HNSCC With Residual Disease After Radiation

NCT02892201
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Pembrolizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 15, 2026, 10:27 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Electromyographic Monitoring and Postoperative Recovery

NCT03891381
View directory record Official record
Conditions
Postoperative Residual Neuromuscular Blockade
Interventions
Tetragraph quantitative monitoring
Device
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Sep 15, 2026, 10:27 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Caris Biorepository Research Protocol

NCT01499394
View directory record Official record
Conditions
Cancer, Early Detection of Cancer, Minimal Residual Disease
Interventions
Not listed
Lead sponsor
Caris Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2035
U.S. locations
38
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia

NCT00789672
View directory record Official record
Conditions
Amblyopia
Interventions
levodopa/carbidopa, patching
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
8 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Early Phase 1 Interventional

Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults with Recurrent or Residual Posterior Fossa Ependymoma

NCT04958486
View directory record Official record
Conditions
Fossa Ependymoma
Interventions
5-Azacytidine and trastuzumab infusion
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 15, 2026, 10:27 AM EDT
Completed No phase listed Observational

Assessment of Third Trimester Post-void Residual and Validation of Bladder Scanner in Pregnancy and Post-partum

NCT00782730
View directory record Official record
Conditions
Pregnancy
Interventions
Not listed
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Sep 15, 2026, 10:27 AM EDT